Klacid I.V. (Clarithromycin)

Clarithromycin binds to the bacterial 50S ribosomal subunit, blocking the translocation step of protein synthesis. This inhibition stops the elongation of the peptide chain, producing a bacteriostatic effect that limits growth of susceptible Gram‑positive, some Gram‑negative and atypical organisms.

The appropriate dose of Klacid I.V. is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local antimicrobial guidelines. No fixed regimen is provided here.

Clarithromycin is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so clinicians should weigh benefits against possible exposure to the infant.

To order Klacid I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Klacid I.V. delivers clarithromycin intravenously, offering rapid plasma concentrations useful for severe infections. Compared with oral macrolides such as azithromycin, it provides higher bioavailability and is preferred when oral intake is not feasible. Relative to other classes like beta‑lactams, clarithromycin has activity against atypical pathogens but may have more drug‑interaction potential.

Klacid I.V. should be stored below 25 °C, protected from moisture and light, and kept in its original packaging until use. Once reconstituted, follow the manufacturer’s instructions for stability and discard any unused solution after the recommended time.

Klacid I.V. is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber according to the patient’s clinical condition and institutional protocols.

Serious risks include hepatotoxicity, QT‑interval prolongation that can lead to arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for liver function abnormalities, cardiac rhythm changes, and any signs of hypersensitivity.

Klacid I.V. should be avoided in patients with known hypersensitivity to clarithromycin or other macrolides, those with a history of significant QT prolongation, and individuals taking medications that strongly interact (e.g., certain statins, ergot derivatives) unless the benefits outweigh the risks.